Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 4/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30951299 | 1.00 | ENPP1 (0.39) | ENPP1ENPP3NT5ENOTUMGLP1R | |
| SCHEMBL24709252 | 0.78 | S1PR4 (0.31) | S1PR4 | |
| SCHEMBL10748633 | 0.77 | XPO1 (0.41) | ENPP1ENPP3NT5ENOTUMGLP1R | |
| SCHEMBL29411821 | 0.77 | ENPP1 (0.41) | ENPP1ENPP3KDM4E | |
| SCHEMBL19715634 | 0.77 | ENPP1 (0.41) | ENPP1ENPP3KDM4E | |
| SCHEMBL30066802 | 0.76 | ENPP3 (0.33) | ENPP1ENPP3 | |
| SCHEMBL29844684 | 0.75 | TNKS (0.33) | — | |
| SCHEMBL23214022 | 0.75 | TNKS (0.33) | — | |
| SCHEMBL18908988 | 0.74 | NOTUM (0.41) | ENPP1ENPP3NT5ENOTUMGLP1R | |
| SCHEMBL19456705 | 0.74 | BACE1 (0.40) | ENPP1ENPP3NOTUMGLP1RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-117881664-A | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4334293-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20220380338-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235859-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| EP-2649053-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| CN-103347864-A | For treating diseases caused by Lp-PLA2Pyrimidone compounds for mediated diseases or conditions | GLAXO GROUP LTD | 2013-10-09 | — | — | CN | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | ENPP1 88/4885ENPP3 108/4885NT5E 1206/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | ENPP1 88/4885ENPP3 108/4885NT5E 1206/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | ENPP1 1908/4885ENPP3 3513/4885NT5E 1254/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | ENPP1 33/4885ENPP3 53/4885NT5E 890/4885 |
| US-20220380338-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | ENPP1 803/4885ENPP3 696/4885NT5E 1006/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | ENPP1 4229/4885ENPP3 3569/4885NT5E 2643/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | ENPP1 30/4885ENPP3 52/4885NT5E 925/4885 |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | AADAT, SLC1A2, SLC1A1 | ENPP1 2409/4885ENPP3 2240/4885NT5E 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.